Fosun medicine: Fosun Kate products obtained drug registration certificate
Fosun Pharmaceutical announced that Fosun Kate, invested by the company, received the "drug registration certificate" issued by the State Drug Administration, and its application for listing and registration of CD19 target auto car-t cell therapy product agilunsai injection was approved by the State Drug Administration.
This text is a result of machine translation.
Related companies：
In-depth
Healthcare
China's First Oral COVID-19 Antiviral Medicine in Dispute
An obscure Chinese company called Genuine Biotech(Chinese: 真实生物) was suddenly put under the spotlight on July 25 when the Chinese authority announced the conditional approval of the company's application for adding the treatment of COVID-19 as a new indication of Azvudine under the special review and approval procedures for drug registration.
Aug 08, 2022 09:00 AM
Nov 16, 2022 05:19 PM
Nov 07, 2022 04:27 PM
Aug 29, 2022 05:45 PM
Apr 28, 2022 08:00 PM
Healthcare, Financials
Fosun Pharma Net Profit down 45% in Q1 2022 as Value of Financial Assets Slumps
Founded in 1994, Shanghai Fosun Pharma is a global pharmaceutical and health group rooted in China and driven by innovation. Its businesses include pharmaceuticals, medical devices and diagnosis, medical and health services. The group covers the pharmaceutical field through participation in Sinopharm Holdings.
Apr 27, 2022 10:55 PM
Briefing Feb 17, 2022 10:08 AM
Yingsi intelligence and Fosun Pharmaceutical reached the first milestone of strategic cooperation: nomination and targeting cd47-sirp α Small molecule compounds of signal pathway
Briefing Jan 24, 2022 02:39 PM
The main force continued to increase its position in lithium battery stocks in the late trading, and sold off banks and pharmaceutical stocks
See more
Read next
Insight
In-depth
Consumer Staples · Analysis
China’s “Dark Cuisine” and Southeast Asia’s Wealth Code
Apr 07, 2025 03:46 PM
Insight
In-depth
Insight
In-depth
